

Segment	Major Product	Existing	Expansion	Total	Sept Qtr	Dec Qtr	Growth %	Company Comments
		MT/Annum			Amt (In Lakhs)			
Anti-hypertensive	Atenolol	300	120	420	1,081.82	1,418.22	31%	Received US FDA approval for its Anti-hypertensive Drug Atenolol Plans to capture major share of the US Atenolol market in the next two years.
Macrolides	Azithromycin	30	60	90	2,637.88	3,084.68	17%	During the pandemic, COVID-19, we are manufacturing Azithromycin, an anti-biotic used for its treatment. Addition of new products is to sustain the market competition
Steriles Carbapenems	Meropenem	6	54	60	1,864.23	739.80	-60%	Carbapenem is manufactured as per the planned campaigns. The lower contribution from Carbapenem in Q3 is due to disruption of campaigns owing to COVID-19. Developing complete range of Carbapenams to solidify the Company's position in the segment
Steriles Cephalosporin	Ceftriaxone	96	84	180	718.79	702.83	-2%	
Neuromodulator	Pregabalin	30	30	60	605.23	317.03	-48%	
<b>Anti-thrombosis</b>	<b>Ticagrelor</b>		<b>6</b>	<b>6</b>	<b>0.81</b>	<b>72.35</b>	<b>8832%</b>	<b>It is used for the prevention of stroke, heart attack and problems with blood supply in the coronary arteries. Got Commercialized in the current quarter Q3 2020-21</b>
Urological	Nitroxoline		33	33	103.34	43.02	-58%	
Gastroenterology					15.94	83.69	425%	
Advance Intermediate					0.00	105.84	100%	
Anti-infective/Anti Acne					6.32	6.79	7%	
Other API Product sales				0	101.98	307.92	202%	
Anti Diabetics	Canagliflozi/ Dapagliflozin		6	6				Developing Anti-diabetic portfolio
	Other Drugs	6	63	69				
Formulations					4,951.87	4,508.09	-9%	
<b>Total</b>		<b>468</b>	<b>456</b>	<b>924</b>	<b>12,088.21</b>	<b>11,390.26</b>		